These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 30555967)
1. The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab. Unsal E; Cubuk MO J Curr Ophthalmol; 2018 Dec; 30(4):337-342. PubMed ID: 30555967 [TBL] [Abstract][Full Text] [Related]
3. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration. Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583 [TBL] [Abstract][Full Text] [Related]
6. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Grewal DS; Gill MK; Sarezky D; Lyon AT; Mirza RG Eye (Lond); 2014 Jul; 28(7):895-9. PubMed ID: 24833178 [TBL] [Abstract][Full Text] [Related]
7. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration. Abu Dail Y; Seitz B; Sideroudi H; Abdin AD Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883 [TBL] [Abstract][Full Text] [Related]
8. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756 [TBL] [Abstract][Full Text] [Related]
10. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab. Spooner K; Fraser-Bell S; Hong T; Chang A Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950 [TBL] [Abstract][Full Text] [Related]
11. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Cho H; Shah CP; Weber M; Heier JS Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432 [TBL] [Abstract][Full Text] [Related]
12. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration. Inan S; Polat O; Karadas M; Inan UU Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625 [No Abstract] [Full Text] [Related]
13. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684 [TBL] [Abstract][Full Text] [Related]
14. Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration. Wang Z; Li M; Yao Y; Hu J; Tang J; Tang R; Piao Z; Qu J J Ophthalmol; 2020; 2020():9340356. PubMed ID: 33005448 [TBL] [Abstract][Full Text] [Related]
15. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Fassnacht-Riederle H; Becker M; Graf N; Michels S Graefes Arch Clin Exp Ophthalmol; 2014 Nov; 252(11):1705-9. PubMed ID: 24614949 [TBL] [Abstract][Full Text] [Related]
16. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Chan CK; Jain A; Sadda S; Varshney N Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034 [TBL] [Abstract][Full Text] [Related]
17. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101 [TBL] [Abstract][Full Text] [Related]
18. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Jørstad ØK; Faber RT; Moe MC Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485 [TBL] [Abstract][Full Text] [Related]
19. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months. Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046 [TBL] [Abstract][Full Text] [Related]
20. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration. Rouvas A; Chatziralli I; Androu A; Mpougatsou P; Alonistiotis D; Douvali M; Kabanarou SA; Theodossiadis P Int Ophthalmol; 2019 Feb; 39(2):431-440. PubMed ID: 29404860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]